BioCentury
ARTICLE | Regulation

Tivozanib, at last, is Aveo’s first approved drug in the U.S. 

More than $200M and a new Phase III trial later, tivozanib reaches the market for kidney cancer

March 11, 2021 3:04 AM UTC

After nine years and more than $200 million raised since Aveo first submitted tivozanib to FDA in 2012, the drug has been approved by the agency for renal cell carcinoma, giving the company its first approved drug in the U.S.

Shares of Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rose 89% to $15.28 in the hour of trading left after the approval’s announcement, giving the company a market cap approaching $450 million. The stock gained a further 29% to $19.70 in after-hours trading...

BCIQ Company Profiles

Aveo Oncology Inc.